Floatz logo

VALSARTAN

Type 2 Diabetes (T2DM)

Myopharm LimitedSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

141 Active assets in the Type 2 Diabetes (T2DM) cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

VALSARTAN is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
77 / 100
View asset →
essential hypertensionDormant
BB
Indicative ·
69 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →